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Antibody(RSV) is a common cause of severe lower respiratory tract infections. Protection
against infection with RSV can be achieved by monthly administration of the humanized monoclonal
antibody palivizumab. The present study analyzes if genetic delivery of a murine version of palivizumab by
single administration would achieve high-level and sustained antibody expression to protect mice against
pulmonary infection with RSV. A murine version of the palivizumab antibody was constructed by replacing
the human sequences with sequences from the constant region of a murine IgG1 antibody, while preserving
the complementarity-determining region. As a proof-of-principle to test the validity of the strategy, the
coding sequence for the heavy and light chains were cloned into a replication-defective serotype 5 human
adenovirus vector (AdαRSV). Antibody expression and speciﬁcity for RSV was conﬁrmed byWestern analysis.
To determine if AdαRSV would mediate production of anti-RSV antibodies in vivo, 5×1010 particle units of
AdαRSV or a control vector without transgene (AdNull), were administered intravenously to BALB/c mice.
RSV neutralizing antibodies were detected in the serum after 4 days in mice receiving AdαRSV but not in
AdNull-infected or naive mice (pb0.05). The mice that had received AdαRSV had at least 5.4-fold lower RSV
titers in the lung 4 days following intranasal challenge with RSV compared to the AdNull or naive group
(pb0.01). To evaluate long-term protection, the antibody construct was expressed in a non-human primate
serotype rh.10 adeno-associated virus vector (AAVrh.10αRSV). RSV neutralizing antibodies were detected in
serum and bronchoalveolar lavage ﬂuid for up to 21 wk following intrapleural administration of
AAVrh.10αRSV, but not with a control AAV vector expressing an unrelated transgene (AAVrh.10α1AT).
Following challenge with RSV at 7 or 21 wk, 14.3-fold and 10.6-fold lower RSV titers were observed after 4
days in the lungs of mice that had received AAVrh.10αRSV compared to AAVrh.10α1AT (pb0.05). Together
these data demonstrate that a gene transfer strategy for delivery of an anti-RSV antibody can generate
protective immunity in mice against RSV infection in the respiratory tract and may provide an alternative to
the administration of the antibody itself.
© 2008 Published by Elsevier Inc.IntroductionRespiratory syncytial virus (RSV) is a major cause of severe lower
respiratory tract infections in high-risk populations, such as infants,
young children, the elderly and patients with chronic lung and heart
disease or immunodeﬁciency (Hall, 2001; Smyth and Openshaw,
2006). Early severe infections with RSV have been associated with the
development of recurrent wheezing or asthma (Perez-Yarza et al.,
2007; Smyth and Openshaw, 2006). Treatment for RSV infection is
limited to supportive care, often requiring prolonged mechanical
ventilation (Hall, 2001; Smyth and Openshaw, 2006). As a licensed
active vaccine for RSV is not available (Bennett et al., 2007; Polack andicine, Weill Medical College of
New York 10065, USA. Fax: +1
. Worgall).
lsevier Inc.Karron, 2004), the only preventive strategy to date is passive im-
munization with a monoclonal antibody or RSV immunoglobulin
(Groothuis and Nishida, 2002; Mejias et al., 2005; The IMpact-RSV
Study Group, 1998; Wu et al., 2008). Intramuscular administration of
palivizumab, a recombinant humanized murine IgG1 antibody against
a neutralizing epitope in the F-glycoprotein of RSV, to high-risk
populations during the RSV peak season in the fall and winter has
decreased RSV-related hospitalizations and morbidity (The IMpact-
RSV Study Group, 1998). The antibody needs to be administered
monthly and, due to its cost, is only available to high-risk populations
(Groothuis et al., 1993; Nuijten et al., 2007).
Genetic delivery of antibodies using gene transfer vectors is a novel,
attractive experimental strategy to achieve prolonged expression of a
therapeutic antibody. Avariety of viral vector systems have been used to
express antibodymolecules, including two of the most commonly used
gene transfer vector systems, adenovirus (Ad) and adeno-associated
virus (AAV) (BenAmmar-Ceccoli et al., 2001; Fang et al., 2005, 2007;
Fig. 1. Expression of a full length anti-RSV mouse monoclonal antibody in vitro. Supernatant of 293 cells transfected with the pShuttleCMVαRSV or a pShuttleCMV control plasmid
were collected at 48 h and analyzed by Western analysis. A. Expression of the IgG1 heavy chain using an anti-mouse IgG1 antibody under non-denaturing conditions in cell
supernatants transfected with pShuttleCMVαRSV (lane 1) or pShuttleCMV control plasmid (lane 2). Murine IgG1 control (lane 3). B. Expression of the IgG1 heavy chain using an anti-
mouse IgG1 antibody under denaturing conditions in cell supernatants transfected with pShuttleCMVαRSV (lane 4) or pShuttleCMV control plasmid (lane 5). Murine IgG1 control
(lane 6). C. Expression of the light chain using an anti-kappa antibody under denaturing conditions in cell supernatants transfected with pShuttleCMVαRSV (lane 7) or pShuttleCMV
control plasmid (lane 8). Murine IgG1 control (lane 9). D. Binding to RSV. Puriﬁed RSV was resolved in a 4 to 12% native polyacrylamide gel and transferred onto a PVDF membrane.
The blot was developed with the supernatant of cells transfected with pShuttleCMVαRSV (lane 10), pShuttleCMV control plasmid (lane 11) followed by anti-mouse IgG-HRP.
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2001; Noel et al., 2002; Prosniak et al., 2003; Jiang et al., 2006). Ad
vectors generally achieve high levels of transgene expression with
limited duration due to the clearance by the immune system and AAV
vectors generally provide long-termexpressionwith less immunological
responses (Hackett et al., 2000). For the present study, we hypothesized
that genetic delivery of amurine equivalent of palivizumabwould result
in sufﬁcient expression of the anti-RSV antibodies to protect against
pulmonary RSV infection in a murine model. Ad group C serotype 5
(AdαRSV) and AAV rhesus macaque serotype rh.10 (AAVrh.10αRSV)
were designed to deliver the coding sequences for the heavy and light
chains of the murine equivalent of palivizumab.
The data demonstrates that systemic administration of AdαRSV
results in efﬁcient shortterm expression of anti-RSV neutralizing
antibody activity to protect mice against an intranasal challenge with
RSV, and that intrapleural administration of AAVrh.10αRSV results in
protective anti-RSV neutralizing antibody activity in serum and lung
epithelialﬂuid for up to 23wk. These observations suggest that genetic
delivery of an anti-RSV antibody can result in long-term anti-RSV
protective immunity and that this strategy might be useful to achieve
long-term passive immunization against other pulmonary pathogens.Fig. 2. RSV antibodies in serum following intravenous administration of AdαRSV.
AdαRSV or AdNull (2×1010 pu) were administered to BALB/c mice (n=5). Serum was
collected after 3 days and analyzed for anti-RSV neutralizing antibodies. Data is
presented as mean±SEM. ⁎ denotes pb0.05 compared to naive and AdNull group. The
dashed line indicates the level of detection.Results
Expression of anti-RSV antibody in vitro
To evaluate the expression of the anti-RSV antibody, 293 cells were
transfected with the pShuttleCMVαRSV or a pShuttleCMV control
plasmid. Cell supernatants were collected after 72 h and the
expression of the antibody was assessed by Western analysis (Fig. 1).
Under non-reducing conditions, a complex of 150 kDa corresponding
to the size of the completely assembled antibody was detected in the
cells transfected with pShuttleCMVαRSV (Fig. 1A, lane 1) but not with
the control plasmid (lane 2). Under reducing conditions, individual
heavy (50 kDa; Fig. 1B) and light (25 kDa, Fig. 1C) chains were detected
in the cells transfected with the pShuttleCMVαRSV (lane 4, Fig. 1B and
lane 7, Fig. 1C) but not with the control plasmid (lane 5, Fig. 1B and
lane 8, Fig. 1C). Binding to RSV was detected with supernatants from
cells transfected with pShuttleCMVαRSV (lane 10, Fig. 1D) but not
with the control plasmid (lane 11).Fig. 3. Protection against RSV lung infection following AdαRSV. AdαRSV or AdNull
(2×1010 pu) were administered intravenously to BALB/c mice (n=5). Seven days later,
mice were challenged with RSV (106 pfu) by intranasal administration. Lungs were
homogenized 4 days following challenge and the number of RSV PFU counts
determined by lung plaque assay. Data is presented as mean±SEM of PFU counts per
gram of lung. ⁎⁎denotes pb0.001 compared to naive and AdNull groups.
Fig. 4. Expression of a full length anti-RSV mouse monoclonal antibody in cells infected with AAVrh.10αRSV. 293orf6 cells were infected with 104 genome copies per cell of
AAVrh.10αRSV or AAVrh.10α1AT as a negative control. Anti-RSV antibody expression was analyzed 3 days following infection in the cell supernatants by Western analysis. A.
Expression of the IgG1 antibody using an anti-mouse IgG1 antibody under non-denaturing conditions in cell supernatants infected with AAVrh.10αRSV (lane 1) or AAVrh.10α1AT
(lane 2). B. Expression of the IgG1 antibody using an anti-mouse IgG1 antibody under denaturing conditions in supernatants of cells infected with AAVrh.10αRSV (lane 3) or
AAVrh.10α1AT (lane 4). C. Binding to RSV. Puriﬁed RSV was resolved in a 4–12% native polyacrylamide gel and transferred onto a PVDF membrane. The blot was developed with
supernatant from cells infected with AAVrh.10αRSV (lane 5) or AAVrh.10α1AT (lane 6) followed by anti-mouse IgG-HRP.
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To determine if AdαRSV would direct expression of anti-RSV
antibodies in vivo, 5×1010 particle units of AdαRSV or the control
AdNull were administered intravenously to BALB/c mice. Neutralizing
RSV titers were elevated in the AdαRSV infected but not in AdNull-
infected or naive mice (Fig. 2; pb0.05, both comparisons).
To assess protection against lung infection with RSV by AdαRSV,
AdαRSV or AdNull were administered intravenously and the mice were
challenged with RSV 7 days later by intranasal administration of RSV.
The mice that received AdαRSV showed more than 5.4-fold decreased
RSV titers in the lung compared to the AdNull or naive group (pb0.01,
both comparisons; Fig. 3). Together, this indicates that systemic admin-
istration of AdαRSV generates sufﬁcient RSV-neutralizing antibodies
after 7 days to protect themice against a pulmonary infectionwith RSV.
Expression of RSV antibody from AAVrh.10αRSV in vitro
To achieve long-term expression, the antibody construct was
expressed from a serotype rh.10 AAV vector. To evaluate expressionFig. 5. Serum and lung RSV neutralizing antibodies following intrapleural administratio
intrapleurally to BALB/c mice (n=5/group). RSV neutralizing antibodies were determined in
following vector administration by neutralizing antibody assay. The sera or BAL of naive m
neutralizing antibodies in serum. B. RSV neutralizing antibodies in BAL. Data is presented aof the anti-RSV antibody by the AAVrh.10αRSV vector in vitro, 293 cells
were infected with either AAVrh.10αRSV or a control vector AAVr-
h.10α1AT, and bindingof the anti-RSV antibody in the supernatantwas
evaluated byWestern analysis (Fig. 4). Under non-reducing conditions,
a complex of 150 kDa corresponding to the size of the completely
assembled antibody was detected in AAVrh.10αRSV-infected cells
(lane 2, Fig. 4A) but not in AAVrh.10α1AT-infected cells (lane 1). Under
non-reducing conditions, heavy (50 kDa) and light (25 kDa) chains
were detected in AAVrh.10αRSV-infected cells (lane 4, Fig. 4B) but not
in AAVrh.10α1AT-infected cells (lane 3). Binding to RSV was detected
with supernatants from AAVrh.10αRSV-infected cells (lane 6, Fig. 4C)
but not with supernatants from AAVrh.10α1AT-infected cells (lane 5).
Intrapleural administration of AAVrh.10αRSV
To determine if AAVrh.10αRSV would mediate production of anti-
RSV antibodies in vivo, 1011 genome copies of AAVrh.10αRSV or the
control vector AAVrh.10α1AT were administered intrapleurally, a route
that had previously resulted in high levels of systemic transgene ex-
pression with an AAVrh.10 vector (De et al., 2004). Mice that hadn of AAVrh10αRSV. AAVrh.10αRSV or AAVrh.10α1-AT (1011 gc) were administered
serum at 0, 4, 8, 12, 16 and 20 wk and in bronchoalveolar lavage ﬂuid (BAL) at 23 wk
ice and mice immunized with AAVrh.10α1AT were used as negative controls. A. RSV
s mean±SEM. ⁎⁎denotes pb0.01 compared to naive and AAVrh.10α1AT group.
Fig. 6. Protection against RSV lung infection following AAVrh.10αRSV administration. AAVrh.10αRSV or AAVrh.10α1-AT (1011 gc) were administered intrapleurally to female BALB/c
mice (n=5/group). Seven and 21 wk later the mice were challenged with RSV (106 pfu) by intranasal administration. Lungs were homogenized 4 days following challenge and the
number of RSV PFU counts determined by lung plaque assay. A. 7 wk. B. 21 wk. Shown is mean±SEM of PFU counts per gram of lung. ⁎denotes pb0.05 and ⁎⁎denotes pb0.001
compared to naive and AAVrh.10α1AT group.
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titers as early as 8 wk post-administration for up to 20 wk (Fig. 5A). No
anti-RSV antibodies were detected in the serum of mice that received
the control vector or in the serum of naive mice. Interestingly, RSV
neutralizing antibodieswere elevated in BALafter 21wk in themice that
had received AAVrh.10αRSV compared AAVrh.10α1AT or naive mice
(pb0.05; Fig. 5B).
To assess protection against RSVbyAAVrh.10αRSV, AAVrh.10αRSVor
AAVrh.10α1AT were administered intrapleurally and the mice were
challenged with RSV at 7 and 21 wk post-administration. Mice that had
received AAVrh.10αRSV showed 14.3-fold and 10.6-fold lower numbers
of RSV pfu in the lung compared to the AAVrh.10α1AT and naive groups
at 7 and 21wk (pb0.05, both comparisons; Fig. 6). These results indicate
that protection against RSV can be sustained at least until 21 wk.
Discussion
Palivizumab is the onlymonoclonal antibody that has been licensed
and widely used for an infectious disease (Casadevall et al., 2004). The
present study investigates if genetic delivery of a murine form of
palivizumab could be used as an alternative mode of delivery of a
puriﬁed anti-RSV antibody preparation to provide protection against
RSV. The data demonstrates that systemic administration of AdαRSV
results in efﬁcient short-term expression of anti-RSV neutralizing
antibody activity to protect mice against a pulmonary infection with
RSV, and that intrapleural administration of AAVrh.10αRSV results in
protective anti-RSV neutralizing antibody activity in serum and
bronchoalveolar lavage ﬂuid for up to 21wk. This suggests that genetic
delivery of an anti-RSV antibody can result in long-term anti-RSV
protective immunity and that this strategy might be useful to achieve
long-term passive immunization against other pulmonary pathogens.
Antibody therapy against RSV
Passive antibody therapy has been successfully used against many
microorganisms (Casadevall et al., 2004; Buchwald and Pirofski, 2003).
Monoclonal antibodies have been developed for therapeutic use, but
interestingly, RSV is the only infectious agent for which a monoclonal
antibody has been licensed, now widely used for almost 10 yr
(Groothuis et al., 1993; The IMpact-RSV Study Group, 1998). RSV is
the leading cause of severe lower respiratory tract infections in infants
and children (Hall, 2001; Smyth and Openshaw, 2006). A licensed
active vaccine is not available and efforts have been challenged by the
failure more than 30 yr ago of a formalin-inactivated vaccine that was
associated with exaggerated Th2 responses and respiratory disease onsubsequent infection with RSV following vaccination (van Drunen
Littel- van den Hurk et al., 2007). There is no effective therapy and
passive immunization with either RSV hyperimmune globulin or the
monoclonal antibody palivizumab, and its newer version motavizu-
mab (Wu et al., 2007), have been effective in diminishing disease
severity in the high-risk populations (Mejias et al., 2005; Wu et al.,
2007; Groothuis and Nishida, 2002; Groothuis et al.,1993; The IMpact-
RSV Study Group, 1998). Palivizumab is an IgG1 humanized mono-
clonal antibody against a neutralizing epitope in the A-antigenic site of
the F-glycoprotein of RSV (Johnson et al.,1997). Due to its high cost, the
antibody is only regularly provided to high-risk groups of premature
infants and needs to be administeredmonthly (Groothuis and Nishida,
2002; Nuijten et al., 2007). An ideal passive immunization strategy
would be a single administration with protective immunity lasting
through the vulnerable period or a least throughout the RSV season. In
the present study, we constructed a genetic murine equivalent of
palivizumab by replacing the human sequences of the constant region
with the sequence from the constant region of a murine IgG1 antibody
while preserving the complementarity-determining region to gener-
ate an antibody that could be tested in a murine model without
inducing immunity against the human portion of the antibody.
Genetic delivery of therapeutic antibodies
Genetic transfer of therapeutic antibodies is an attractive strategy
to achieve long-term persistence of the antibody. Antibody molecules
have been expressed using a variety of viral vector systems, including
adenovirus, AAV, vaccinia virus, baculovirus and rhabdovirus (BenAm-
mar-Ceccoli et al., 2001; Fanget al., 2005, 2007; Koch et al., 2003; Lewis
et al., 2002; Liang et al., 1997; Morimoto et al., 2001; Noel et al., 2002;
Prosniak et al., 2003; Jiang et al., 2006). In the present study, a full
length antibody that bound and neutralized RSVwas expressed in two
viral vector systems: an Ad vector, where the light and heavy chain
genes were separated using a poliovirus IRES, and in an AAV serotype
rh.10 vector, with the heavy and light chains separated by a furin
cleavage site and the self-cleaving peptide from the foot-and-mouth
disease virus. These platforms have been previously shown to
efﬁciently express a full length antibody against protective antigen
(PA) of Bacillus anthracis delivered by an Ad vector (De et al., 2007). In
general, long-termpersistence of antibodies expressed byAd vectors is
impaired by the immune response against the Ad vector, although
expression for up to 4 wk has been demonstrated for an anti-HER-2
monoclonal antibody (Jiang et al., 2006) and 3 months following
delivery of an anti-thyroglobulin antibody (Noel et al., 2002).
Transgene expression following Ad5-mediated gene transfer to
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antibodies following genetic delivery can be achieved using AAV
vectors. For AAV vectors prolonged expression of an antibody for at
least 6 months has been demonstrated with an AAVrh.10 serotype
vector expressing an antibody against PA of B. anthracis (De et al.,
2007), with an AAV2 vector for the HIV monoclonal antibody anti-
gp120 (Lewis et al., 2002), andwith anAAV8 vector for an anti-vascular
endothelial growth factor receptor 2 antibody (Fang et al., 2005; Lewis
et al., 2002). In the present study, sustained levels of the anti-RSV
antibody in serum and bronchoalveolar lavage ﬂuid were seen for at
least 3 months with no difference in the protective effect against an
RSV pulmonary infection between mice challenged after 7 or 21 wk.
The reduction in RSV titers following challenge with RSV, although
signiﬁcant, was only moderate in magnitude. Future studies will need
to assess antibody constructs with increased afﬁnity such as
motavizumab. In this study, to circumvent possible interference of
the human parts of palivizumab, the human sequences were replaced
by murine sequences. Future studies of gentic delivery of humanized
antibodies should include an analysis of the immune recognition of the
humanized antibody (which has been shown to work efﬁciently in
mice) a theoretical concern if antibodies are being expressed over a
prolonged period using AAV vector systems.
In summary, genetic delivery of an anti-RSV antibody is feasible to
achieve long-term protection against pulmonary infection with RSV
and could provide an alternative passive immunization strategy for
this and other pulmonary infectious diseases.
Methods
Murine anti-RSV antibody construct
A murine form of an anti-RSV antibody (αRSV) was constructed
synthetically based on the sequence of palivizumab (Johnson et al.,
1997). The complementarity-determining region was preserved from
the palivizumab sequence (Beeler and van Wyke Coelingh, 1989) (US
patent 5,824,307) and the human sequences of the remaining parts
of the antibody were replaced with the sequence from the constant
region of a murine IgG1. Overlapping oligonucleotides were chosen
with the DNA Builder software (http://ecce.pnl.gov/help/child/
dna_toolkit). The light chain design consisted of 14 seventy-mers,
overlapping by ~20 bases each, assembled by 2 rounds of PCR
ampliﬁcation. The heavy chain design included 28 seventy-mers,
overlapping by ~20 bases, assembled by 3 rounds of PCR ampliﬁca-
tion. The light and heavy chain genes were separately cloned into
TOPO-expression vectors and sequenced. To facilitate bicistronic
expression of heavy and light chains from a single vector, the light
and heavy chain coding sequences were then both cloned into the
pShuttleCMV plasmid, separated by the poliovirus internal ribosome
entry site (IRES). Accurate orientation was conﬁrmed by restriction
analysis and sequencing.
Ad vectors
The anti-RSV antibody construct was cloned into a ﬁrst generation
E1-E3- Ad vector, encoding the anti-RSV light chain and heavy chain
cDNAs separated by a poliovirus internal ribosome entry site (IRES).
The expression cassette in the AdαRSV vector contains (5' to 3') the
cytomegalovirus promoter/enhancer followed by cDNAs encoding the
anti-RSV light chain, the polio virus internal ribosomal entry site
(IRES), the anti-RSV heavy chain, and the SV40 polyadenylation signal.
AdNull, an Ad5 vector containing no transgene in the expression
cassette, was used as a negative control (Hersh et al.,1995). The vectors
were produced in 293 cells and puriﬁed by centrifugation twice
through CsCl gradient as previously described (Rosenfeld et al., 1992),
and the particle units (pu) determined spectrophotometrically
(Mittereder et al., 1996).AAV vectors
AAVrh.10 was chosen based on previous studies demonstrating that
intrapleural adminis- tration of a vector with AAVrh.10 capsid and
AAV2 internal terminal repeats (ITR) yielded the highest serum levels of
α1-antitrypsin (De et al., 2004) and anthrax anti-protective antigen
anti- bodies (De et al., 2007). AAVrh.10αRSV encodes theαRSV antibody
heavy and light chains, separated by furin and self-cleaving 2A protease
sites for expression of the CMVpromoter. The.AAVrh.10αRSV expression
cassette contains (5' to 3') the cytomegalovirus promoter/enhancer
followed by cDNAs encoding theαRSV heavy chain, a 13 amino acidmyc
tag, a 4 amino acid furin cleavage site, the 24 amino acid self-cleaving 2A
peptide from foot-and-mouth disease virus (De et al., 2006; Fang et al.,
2005), the αRSV light chain and the human growth hormone poly-
adenylation signal. All recombinant AAVrh.10 vectors were produced
using a three plasmid system: (1) an expression plasmid (pAAVαRSV for
the vectors expressing αRSV antibody or pAAVα1AT for vectors
expressing α1AT); (2) pAAV44.2, an AAVrh.10 packaging plasmid that
provides the AAV Rep proteins (derived from AAV) needed for vector
replication and the viral structural (cap) proteins VP1, 2, and 3 derived
from AAVrh.10, which determines the serotype of the AAV vector; and
(3) pAdDeltaF6, an Ad helper plasmid that provides the Ad helper
functions of E2, E4 andVARNA (Gao et al., 2004; Rabinowitz et al., 2002;
Xiao et al., 1998). For AAVrh.10 vector production, the expression
plasmid pAAVαRSV or the α1AT expression plasmid pAAVα1AT, the
AAVrh.10 packaging plasmid pAAV44.2, and helper plasmid pAdDeltaF6
were cotransfected in 293 cells. The AAVrh.10-based vectors were
puriﬁed, concentrated and the vector genome titers determined by Taq-
Man real-time PCR as previously described (De et al., 2006).
RSV
RSV strain A2 (VR-1540, ATCC, Manassas, VA) was grown and
quantiﬁed on Hep-2 cells and was prepared as described. Hep-2 cells
were maintained in Eagle-modiﬁed minimum essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin.
Expression of anti-RSV antibodies in vitro
Expression of the anti-RSV antibody fromAdαRSV or AAVrh10αRSV
following infection of cells in vitro was evaluated by Western analysis.
A549 cells were transfected with the pShuttleCMVαRSV or a pShut-
tleCMVcontrol plasmid and supernatantswereharvested after 48h. 293
orf6 cells were infected with AAVrh.10αRSV and supernatants were
harvested after 72 h. All supernatants were resolved by SDS-poly-
acrylamide gel electropheresis under non- reducing or reducing
conditions followed byWestern analysis using a horseradish peroxidase
conjugatedgoat anti-mouse IgG1 (Santa CruzBiotechnology, Santa Cruz,
CA) for detection of full length antibody and the heavy chain or a goat
anti-mouse kappa antibody (Santa Cruz Biotechnology) for the light
chain followed by ECL reagent (Amersham, Piscataway, NJ). Binding of
the antibodies to RSVwas evaluated by separating RSV [1.2×107 plaque-
forming units (PFU)] in a 4–12% native polyacrylamide gel andWestern
analysis. The analysis was carried out with antibody-containing cell
supernatant followed by anti-mouse IgG-HRP and ECL reagent.
Administration of Ad and AAV vectors to mice
AdαRSV or AdNull (2×1010 particle units) were administered via
the tail vein to BALB/c mice. AAVrh.10αRSV or AAVrh.10 α1AT (1011
genome copies),weredelivered into the pleural space of the left lungof
6 wk old female BALB/c mice. The AAV vectors were administered in
50 μl following a thoracotomy in the third intercostal space through the
exposed pleural space using a pipette (De et al., 2004). The dose of the
AAV vector was chosen based on efﬁcient gene transfer to the pleura of
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antibody (De et al., 2007).
Assessment of RSV neutralizing antibodies in vivo
To evaluate anti-RSV neutralizing antibody titers in serum and
bronchoalveolar lavage following intravenous administration of AdαRSV
or AdNull (2×1010 particle units), or intrapleural administration of
AAVrh.10αRSV or AAVrh.10α1AT (1011 genome copies), the vectors were
administered intravenously (Ad vectors) or to the left pleural cavity (AAV
vectors) of 6wkold femaleBALB/cmice.Naivemice thathad receivedPBS
either intravenously or intrapleurally served as additional controls. Sera
from the Ad-immunized mice were collected at 3 days post-administra-
tion and sera fromAAVrh.10-immunizedmicewere collected at 2, 4, 8,12,
16 and 21 wk following vector administration. Bronchoalveolar lavage
(BAL) was performed by three intratracheal instillations and removal of
1 ml PBS, pH 7.4 at 23 wk following vector administration. BAL ﬂuid was
centrifuged at 6000 rpm at 4 °C, 20 min. Serial dilutions of sera and BAL
ﬂuid in infection medium (MEM supplemented with 1% penicillin/
streptomycin) were incubated with RSV (strain A2) for 11 h at 37 °C and
then incubated on Hep2 cells for 90 min at 37 °C. The mediumwas then
changed to 1% methylcellulose medium (with MEM, 5% fetal bovine
serum, 1% penicillin/streptomycin). Palivizumab (Synagis, 1 μg/ml;
Medimmune, Gaithersburg, MD) was used as a positive control for the
neutralizing antibody assay. After 4 days, the cells were ﬁxed with 4%
paraformaldehyde for 10 min, stained with 1% crystal violet and the
plaques counted under a microscope.
Protection of mice from intranasal challenge with RSV
To evaluate protection against RSV infection of the respiratory tract
following adminis- tration of AdαRSV or AAVrh.10αRSV, BALB/c mice
received either AdαRSV or AdNull (2×1010 pu) intravenously or
AAVrh.10αRSV or AAVrh.10α1AT (1011 gc) intrapleurally. The mice that
had received the Ad vectors were challenged with RSV 7 days following
vector administration; the mice that had received the AAVrh.10 vectors
were challenged at 7 and 21 wk following vector administration. Follow-
inganaesthesiawith isoﬂurane themicewere intranasally inoculatedwith
RSV (106 pfu). Four days later the mice were sacriﬁced, the lungs
homogenized in 1mlMEM (supplemented with 1% penicillin/streptomy-
cin) and the homogenate centrifuged at 1200 rpm at 4 °C for 10min. Ten-
fold serial dilutions of the lung homogenate supernatant were incubated
in infectionmediumonHep2 cells for 33h at 37 °C. Themediumwas then
replaced with 1% methylcellulose medium (with MEM, 5% fetal bovine
serum, 1% penicillin/streptomycin) and incubated for 4 days. The cells
were ﬁxed and the number of PFU's quantiﬁed as outlined above.
Statistics
The data are presented as mean±standard error of the mean.
Statistical analyses were performed using the non-paired two-tailed
Student's t-test, assuming equal variance. Statistical signiﬁcance was
determined at pb0.05.
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